CriticalSSRI×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B)
Updated · Methodology
Mechanism
Fluvoxamine selectively inhibits serotonin reuptake by brain neurons (fluvoxamine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Phenelzine is a potent monoamine oxidase (MAO) inhibitor, and MAO inhibitors block the breakdown of serotonin and noradrenaline (phenelzine label, US Food and Drug Administration, FDA, Description and Precautions). According to the Spanish SmPC, fluvoxamine must not be combined with MAO inhibitors because of the risk of serotonin syndrome (fluvoxamine SmPC, AEMPS, section 4.5). The US phenelzine label reports serious, sometimes fatal, reactions when non-selective MAO inhibitors were combined with serotonergic drugs, fluvoxamine included (FDA phenelzine label, Precautions). Fluvoxamine strongly inhibits the cytochrome P450 (CYP) enzymes CYP1A2 and CYP2C19 and, to a lesser extent, CYP2C9, CYP2D6 and CYP3A4 (fluvoxamine SmPC, AEMPS, sections 4.5 and 5.2). MAO itself oxidises most of the phenelzine in the body (FDA phenelzine label, Clinical Pharmacology). The documents do not say whether fluvoxamine changes the metabolism of phenelzine.
Symptoms
The US phenelzine label reports serious reactions when serotonergic drugs, fluvoxamine included, were combined with a monoamine oxidase (MAO) inhibitor: hyperthermia, rigidity, myoclonic movements and death (phenelzine label, US Food and Drug Administration, FDA, Contraindications). The Spanish fluvoxamine summary of product characteristics (SmPC) describes serotonin syndrome as hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid swings in vital signs, and mental changes ranging from confusion and irritability to extreme agitation that progresses to delirium and coma. These states can be life-threatening (fluvoxamine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). The US fluvoxamine label adds hallucinations, fast heart rate, labile blood pressure, dizziness, sweating, flushing, tremor, hyperreflexia, incoordination, seizures, nausea, vomiting and diarrhoea (FDA fluvoxamine label, section 5.2).
Management
The combination is contraindicated. The Spanish fluvoxamine summary of product characteristics (SmPC) prohibits combining fluvoxamine with monoamine oxidase (MAO) inhibitors (fluvoxamine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). According to its own label, phenelzine is an MAO inhibitor (phenelzine label, US Food and Drug Administration, FDA, Description). The US phenelzine label contraindicates phenelzine with serotonergic drugs and names fluvoxamine (FDA phenelzine label, Contraindications). The US fluvoxamine label contraindicates MAO inhibitors used for psychiatric disorders (FDA fluvoxamine label, section 4), and phenelzine is used for depression (FDA phenelzine label, Indications). Phenelzine is not authorised in Spain (AEMPS medicines register), so information on it comes from the US label. Start fluvoxamine no earlier than 14 days after stopping phenelzine (FDA phenelzine label, Contraindications; FDA fluvoxamine label, sections 2.4 and 4). According to the Spanish fluvoxamine SmPC, fluvoxamine can be started two weeks after an irreversible MAO inhibitor or the next day after a reversible one (fluvoxamine SmPC, AEMPS, section 4.3). Start phenelzine no earlier than 14 days after stopping fluvoxamine (FDA phenelzine label, Contraindications; FDA fluvoxamine label, section 2.4). The Spanish fluvoxamine SmPC gives at least one week (fluvoxamine SmPC, AEMPS, section 4.3). Withdraw fluvoxamine gradually, reducing the dose over at least one to two weeks (fluvoxamine SmPC, AEMPS, section 4.2). If signs of serotonin syndrome appear, stop fluvoxamine and other serotonergic drugs at once and start symptomatic treatment (fluvoxamine SmPC, AEMPS, section 4.4; FDA fluvoxamine label, section 5.2).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Nardil (phenelzine sulfate tablets, USP) – prescribing information (2025)– FDA label, Parke-Davis Div of Pfizer, DailyMed setid 513a41d0-37d4-4355-8a6d-a2c643bce6fa, version 11, 06/2025, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- FDA: Fluvoxamine maleate tablets prescribing information (Apotex) (2026)– Apotex Corp. Fluvoxamine maleate tablets. Prescribing information, DailyMed setid 6eeb14df-6fcf-a737-5359-5744eb4accea, sections 4, 5.8, 5.10 and 7 (Luvox brand is no longer listed)
- AEMPS: Ficha técnica: Dumirox 100 mg, fluvoxamina (nº registro 58212), sección 4.4 (2025)– AEMPS, CIMA, nº registro 58212, revisión 06/2025, sección 4.4
- AEMPS: Ficha técnica: Dumirox 100 mg, fluvoxamina (nº registro 58212), sección 4.3 (2025)– AEMPS, CIMA, nº registro 58212 (Dumirox 100 mg comprimidos recubiertos con película, Viatris), revisión 06/2025, secciones 4.3 y 4.5